Dow & propylene glycol
This article was originally published in The Tan Sheet
Executive SummaryLeading manufacturer of food, drug stabilizer announces 4¢ per lb. increase in off-list prices of ingredient effective June 1. Dow Chemical Company cites "higher costs for propylene monomer and increased natural gas prices" as reasons for the increase. Despite price jump, Dow expects demand for PG will increase during the rest of 2002; PG is used in many OTC drugs, including eye care products, acne medications, nasal sprays, firm says...
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.